Drug Trial Radar · NCT06165250
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Apr 17, 2024
Primary completion
Nov 11, 2025
Study completion Nov 11, 2025
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia
Conditions
- Essential Hypertension
- Primary Hypercholesterolemia
Interventions
BR1018ADrug
One tablet administered alone
BR1018A-1Drug
One tablet administered alone
BR1018BDrug
One tablet administered alone
BR1018B-1Drug
One tablet administered alone
BR1018CDrug
One tablet administered alone
BR1018C-1Drug
One tablet administered alone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean sitting systolic blood pressureTime frame: 8weeks from Baseline Visit
- LDL-CTime frame: 8weeks from Baseline Visit
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Keimyung University Dongsan Hospital
Daegu, South Korea
Seoul National University Boramae Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.